Global ‘Fair Access’ Coronavirus Vaccine Fund Launched, AZ Doubles Output Target
Company Aims For Two Billion Doses A Year
Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.
You may also be interested in...
Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.
As vaccine development progresses, worldwide deaths caused by SARS-CoV-2 continue to rise, and now exceed 500,000, with more than 10 million confirmed cases. Daily new infections also hit a new peak, as some US states are being forced to consider lockdowns again as the situation worsens.
Recruiting the right patient population for Phase III trials of COVID-19 vaccines will be a key factor in how fast any candidate can come to market. The challenge, which will likely mean enrolling patients who often are underrepresented in trials, is keeping Moderna's Chief Medical Officer up at night. The company also talked vaccine distribution, what it feels it owes the US government for its financial support, and pricing of its potential mRNA vaccine on a recent New York Academy of Sciences webinar.